<DOC>
	<DOCNO>NCT00154401</DOCNO>
	<brief_summary>This trial conduct Europe . The trial design show effect treatment liraglutide placebo blood glucose control 14 week subject type 2 diabetes . Liraglutide placebo administer injection daily evening . The trial multi-national trial treatment conceal participate subject , investigator sponsor . Treatment allocation random equal chance assign group .</brief_summary>
	<brief_title>Effect Liraglutide Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes mellitus treat either diet single oral drug therapy Diet treat subject : 7.5 % &lt; HbA1c &lt; 10 % Single oral drug therapy subject : 7.0 % &lt; HbA1c &lt; 9.5 % Body Mass Index ( BMI ) : max 40 kg/m^2 Subjects treat thiazolidinediones insulin Subjects serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>